Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Hepatitis E vaccine in healthy adults
NCT02603055Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEV 239 in hepatitis E (HEV), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Occurrence of adverse reactions. Started Jul 2015; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT02603055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603055.